To explore the use of anlotinib as neoadjuvant therapy in a pediatric patient with locally advanced papillary thyroid carcinoma, highlighting its potential impact on treatment strategies.
Key Findings:
The tumor showed adequate regression after 3 cycles of anlotinib, allowing for surgical resection, indicating the potential effectiveness of this treatment.
No significant adverse drug reactions were reported during treatment, suggesting a favorable safety profile.
Permanent hypoparathyroidism was the only complication post-surgery, highlighting the need for careful monitoring.
Interpretation:
Anlotinib may be a viable neoadjuvant treatment option for pediatric patients with locally advanced thyroid cancer, potentially improving surgical outcomes, but further research is essential.
Limitations:
The study is based on a single case, limiting generalizability and introducing potential biases.
Long-term outcomes and efficacy in a larger cohort remain to be established, necessitating further investigation.
Conclusion:
This case suggests that anlotinib could be beneficial in managing locally advanced papillary thyroid carcinoma in children, warranting further investigation to confirm its efficacy and safety.
